NeoGenomics, Inc. Proceeds from Issuance of Secured Debt
NeoGenomics, Inc. (NEO) reported Proceeds from Issuance of Secured Debt of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2022-02-25
- NeoGenomics, Inc. proceeds from issuance of secured debt for the quarter ending 2020-12-31 was $0.00.
- NeoGenomics, Inc. proceeds from issuance of secured debt for the quarter ending 2020-09-30 was $0.00.
- NeoGenomics, Inc. proceeds from issuance of secured debt for the quarter ending 2019-12-31 was $0.00.
- NeoGenomics, Inc. proceeds from issuance of secured debt for the quarter ending 2019-09-30 was $0.00.
- NeoGenomics, Inc. proceeds from issuance of secured debt for fiscal 2021 was $0.00.
- NeoGenomics, Inc. proceeds from issuance of secured debt for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- NeoGenomics, Inc. proceeds from issuance of secured debt for fiscal 2019 was $100.00M, a 233.33% increase from fiscal 2018.
- NeoGenomics, Inc. proceeds from issuance of secured debt for fiscal 2018 was $30.00M.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 6 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-07-31 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $100.00M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $100.00M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $100.00M 10-Q · filed 2020-07-31 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $30.00M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $30.00M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $30.00M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | $0.00 10-K · filed 2020-02-28 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |